Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2016 Feb;142(2):481-7.
doi: 10.1007/s00432-015-2055-6.

Integrated care in ovarian cancer “IgV Ovar”: results of a German pilot for higher quality in treatment of ovarian cancer

M-D Keyver-Paik, A Abramian, C Domröse, A Döser, T Höller, M Friedrich, W Meier, K Menn, W Kuhn
Multicenter Study

Integrated care in ovarian cancer “IgV Ovar”: results of a German pilot for higher quality in treatment of ovarian cancer

M-D Keyver-Paik et al. J Cancer Res Clin Oncol. 2016 Feb.

Abstract

Introduction: Late-stage ovarian cancer patient's survival depends on complete cytoreduction and chemotherapy. Complete cytoreduction is more often achieved in institutions with a case volume of >20 cases per year. The Integrated care program Ovar (IgV Ovar) was founded in 2005 and started recruiting in 2006 with 21 health insurances and six expert centers of ovarian cancer treatment as a quality initiative. Results of the pilot and outcomes of patients of three participating centers will be presented here.

Methods: Data of 1038 patients with ovarian cancer were collected. Adjuvant patients (n = 505) stage FIGO IIB-IV (n = 307) were analyzed for cytoreduction and survival. FIGO IIIC patients were analyzed separately.

Results: Median follow-up was 32.7 months. Progression-free survival (PFS) was 23.1 months and overall survival (OS) was 53.6 months for stage IIB-IV. Patients with FIGO IIIC were completely cytoreduced in 48 %. PFS was 21, 29 months if completely cytoreduced. OS was 47.4, 64.9 months if completely cytoreduced.D ISCUSSION: Although the IgV Ovar Rhineland proved to have some structural problems with recruitment and prospective data collection, cytoreduction rates and outcome of patients prove treatment of patients in expert centers is superior to the national and international mean. Therefore, a new quality initiative will be started to bring more awareness to women and to their gynecologists and general practitioners of just how important a good referral strategy is.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Progression free survival FIGO IIB-IV in months: PFS in 307 patients with FIGO IIB–IV ovarian cancer was 23.1 months (95 % CI 20.0–26.1 months)
Fig. 2
Fig. 2
Overall survival FIGO IIB-IV in months: OS in 307 patients with FIGO IIB–IV ovarian cancer was 53.6 months (95 % CI 41.6–65.5 months)
Fig. 3
Fig. 3
Kaplan–Meier function of progression-free survival in 198 patients with FIGO IIIC ovarian cancer stratified by cytoreduction
Fig. 4
Fig. 4
Kaplan–Meier function of overall survival in 198 patients with FIGO IIIC ovarian cancer stratified by cytoreduction
Fig. 5
Fig. 5
Cytoreduction: comparison QS-Ovar versus IgV hospitals. Modified after QS-Ovar, Hilpert et al. (2010)
See this image and copyright information in PMC

References

    1. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354(1):34–43 - PubMed
    1. Bristow RE, Santillan A, Diaz-Montes TP, Gardner GJ, Giuntoli RL 2nd, Meisner BC, Frick KD, Armstrong DK (2007) Centralization of care for patients with advanced-stage ovarian cancer: a cost-effectiveness analysis. Cancer 109(8):1513–1522 - PubMed
    1. Bristow RE, Zahurak ML, Diaz-Montes TP, Giuntoli RL, Armstrong DK (2009) Impact of surgeon and hospital ovarian cancer surgical case volume on in-hospital mortality and related short-term outcomes. Gynecol Oncol 115(3):334–338 - PubMed
    1. Bristow RE, Palis BE, Chi DS, Cliby WA (2010) The National Cancer Database report on advanced-stage epithelial ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm. Gynecol Oncol 118(3):262–267 - PubMed
    1. Bristow RE, Chang J, Ziogas A, Randall LM, Anton-Culver H (2014) High-volume ovarian cancer care: survival impact and disparities in access for advanced-stage disease. Gynecol Oncol 132(2):403–410 - PubMed

Publication types

LinkOut - more resources